Updated: Roche’s Genentech wades into radiopharmaceuticals with PeptiDream alliance, $40M upfront
In one of its first forays into radiopharmaceuticals, Roche’s Genentech has lined up a discovery and development pact with the peptide specialists at PeptiDream.
Genentech is handing over $40 million upfront to kick off the deal, which will focus on macrocyclic peptide candidates against targets of its choice to create peptide-radioisotope conjugates. PeptiDream will handle early preclinical development of any resulting candidates before sending them back to Genentech — while keeping Japan rights.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
